FK463

DRUG4 trials

Sponsors

National Cancer Institute (NCI), Astellas Pharma Inc

Conditions

AspergillosisCandidiasisFeverFungemiaMycosesNeutropenia

Phase 1

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia

CompletedNCT00001790

National Cancer Institute (NCI)Fever, Mycoses, Neutropenia

Start: 1998-10-31End: 2000-09-30Target: 120Updated: 2008-03-04

Phase 2

Study of FK463 for the Treatment of Invasive Aspergillosis

CompletedNCT00036166

Astellas Pharma IncAspergillosis

Start: 1999-01-29End: 2002-01-31Updated: 2018-01-10

Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

CompletedNCT00036179

Astellas Pharma IncCandidiasis

Start: 1999-02-27End: 2002-01-27Updated: 2018-01-10

Phase 3

Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients

CompletedNCT00001937

National Cancer Institute (NCI)Aspergillosis, Candidiasis, Fungemia +1

Start: 1999-11-30End: 2000-12-31Target: 800Updated: 2008-03-04